Novartis Generated $40 Billion In Innovative Medicine Sales, Says Ceo

Novartis generated $40 billion in innovative medicine sales, says CEO

CNBC Television

Novartis ‘focusing on high-end, innovative medicines,’ CEO says

Novartis CEO: Spinoffs will see us succeed as a pure-play innovative medicines company

CNBC International News

Novartis CEO: Company set to become a pure play, innovative medicine business after Sandoz spin off

CNBC International News

Novartis not joining the 'frenzy' of weight loss drugs, CEO says

CNBC International News

Novartis CEO: Our leukemia drug Scemblix is a potential $3 billion plus medicine

CNBC Television

Reimagining Medicine with Data & Digital | Novartis CEO at #VivaTech19

Novartis as a focused innovative medicines company

Innovative medicines business returning to growth, Novartis CEO says

CNBC International News

Novartis CEO Vas Narasimhan: Our medicines are starting to take market share and deliver on promises

CNBC Television

Novartis Financial Results Q3 2021

What is the Novartis next generation Technology Platforms strategy?

Novartis CEO: Confident about continued sales growth for rest of year

CNBC International News

Novartis acquires The Medicines Company for $9.7 billion

CNBC Television

Novartis CEO Vas Narasimhan on the latest research on a breast cancer drug

CNBC Television

Novartis CEO: We expect our six key drugs to grow ahead of analyst expectations

CNBC Television

Novartis sees healthy drug market

South China Morning Post

Novartis transformation into a pure-play Innovative Medicines company

"I don’t feel pressure from shareholders," says Novartis CEO Vas Narasimhan

Novartis Raises Outlook After Sandoz Generics Spinoff

Bloomberg Television